Primary Cutaneous Melanoma Pathology Reporting Proforma

Includes the International Collaboration on Cancer reporting dataset denoted by *

Family name

Given name(s)

Date of birth

DD - MM - YYYY

Sex

☐ Male

☐ Female

☐ Intersex/indeterminate

Ethnicity

☐ Unknown

☐ Aboriginal/Torres Strait Islander

☐ Other ethnicity:

Patient identifiers
e.g. MRN, IHI or NHI (please indicate which)

Date of request

DD - MM - YYYY

S1.03 Accession number

Requesting doctor - name and contact details


*Tumour site

Not provided ○ Specify ▼

Specimen laterality

Left ○ Right ○ Midline ○ Not provided ○

Clinical or differential diagnosis


Specimen type

Not provided ○ Excision ○ Punch ○ Incision ○ Curette ○ Shave ○ Re-excision ○ Other ○

If re-excision:

Previous laboratory

Previous lab accession number

Findings in previous biopsy

History & timing of lesional trauma, biopsy, irritation or treatment with topical agent

Past history of melanoma?

No ○

Yes ▶ Details eg site, thickness, timing, treatment

Evidence of metastatic disease?

No ○

Yes ▶ Describe (and consider recording serum LDH below):

Serum lactate dehydrogenase

I.U.

Other relevant history


Details of specimen orientation

Any clinically or dermatoscopically identified suspicious areas?
- No
- Yes  Describe:

Clinical or other relevant diagnostic imaging results

New primary melanoma or recurrence
- New primary
- Recurrence – local
- Recurrence – intransit metastasis
  (between primary site and regional node field)
- Recurrence – regional
- Recurrence – distant
- Not stated

S1.04  Principal clinician caring for the patient

G1.01  Other clinical information received

Macroscopic findings

G2.01  *Specimen description

G2.03  *Specimen dimensions

G2.04  *Specimen orientation

(This refers to the information received from the surgeon regarding orientation of the specimen by marking sutures, clips or other techniques)

- Not provided
- Specify (if known)

G2.05  *Macroscopic primary lesion description

(The description of the lesion includes includes such features as shape, colour, border, contour, evidence of surface crusting or ulceration and proximity to resection margins)

G2.06  *Macroscopic primary lesion dimensions

Indeterminate  (Note: Depth is optional)

G2.07  *Other lesion(s)

- Not identified
- Present

*Macroscopic description of other lesion(s)

(The description of the lesion includes such features as shape, colour, border, contour, evidence of surface crusting or ulceration and its proximity to the primary lesion and the resection margins)

G2.08  *Block identification key
Microscopic findings

S3.01 *Breslow thickness
(Measurement should be to a minimum of 1 decimal point and to a degree of precision as to allow accurate AJCC staging)

Specify ▶ mm
Indeterminate ○
At least ▶ mm

G3.02 *Effacement of subepidermal space

S3.02 *SURGICAL MARGIN/TISSUE EDGES STATUS

*S In situ component: Peripheral margin
- Cannot be assessed ○
- Not involved by melanoma in situ □

Distance of melanoma in situ from closest margin mm
Specify location(s) of closest uninvolved margin if possible
Involved by melanoma in situ □

*S Invasive component: Peripheral margin
- Cannot be assessed ○
- Not involved by invasive melanoma □

Distance of invasive melanoma from closest peripheral margin mm
Specify location(s) of closest uninvolved margin if possible
Involved by invasive melanoma □

*S Invasive component: Deep margin
- Cannot be assessed ○
- Not involved by invasive melanoma □

Specify location(s) of closest uninvolved margin if possible
Involved by invasive melanoma □

*S Specify location(s), involved margins if possible

S3.03 *Ulceration
- Indeterminate ○
- Not identified ○
- Present □

G3.03 *Extent of ulceration mm

S3.04 *Mitotic count mm²

S3.05 *Satellites
- Indeterminate ○
- Not identified ○
- Present □

*S Satellites: margins
- Cannot be assessed ○
- Not involved by satellite ○
- Involved by satellite ○

G3.03 *Clark level
- Confined to epidermis (I)
- Infiltrates but does not fill papillary dermis (II)
- Fills/expands papillary dermis (III)
- Infiltrates into reticular dermis (IV)
- Infiltrates into subcutaneous fat (V)

S3.06 *Lymphovascular invasion
- Indeterminate ○
- Not identified ○
- Present □

G3.04 *Tumour-infiltrating lymphocytes (early regression)
- Not identified ○
- Non-brisk ○
- Brisk ○

G3.05 *Tumour regression (intermediate and late)
- Indeterminate ○
- Not identified ○
- Present □

Extent of regression
width mm x depth mm
**G3.06**  *Tumour regression (intermediate and late): margins*
- Cannot be assessed
- Involved by regression
- Not involved by regression

Clearance from margins of excision

**S3.07**  *Desmoplastic melanoma component*
- Not identified
- Present

*Pure/Mixed*
- Pure desmoplastic melanoma (>90% desmoplastic features)
- Mixed (mixed desmoplastic / non-desmoplastic melanoma)

**S3.08**  *Neurotropism*
- Indeterminate
- Not identified
- Present

**G3.07**  *Associated melanocytic lesion*
- Not identified
- Present

**G3.08**  Intraepidermal melanoma growth pattern
- Pagetoid
- Lentiginous
- Mixed pattern

**G3.09**  *Melanoma subtype*
(1 or more maybe applicable) (Value list modified from the WHO Classification of Tumours. Pathology and Genetics of Skin Tumours. (2005),)
- Superficial spreading melanoma
- Nodular melanoma
- Lentigo maligna melanoma
- Acral-lentiginous melanoma
- Desmoplastic melanoma
- Melanoma arising from blue naevis
- Melanoma arising in giant congenital naevis
- Melanoma of childhood
- Naevoid melanoma
- Persistent melanoma
- Melanoma, not otherwise classified
- Other (specify)

**S3.09**  *LYMPH NODE STATUS*
(If lymph nodes are not received these elements should NOT be reported.)

*No. of sentinel nodes examined*

*No. of positive sentinel nodes*

*Total number of nodes examined (sentinel and non-sentinel)*

*Total number of positive nodes examined (sentinel and non-sentinel)*

**G3.10**  *Sentinel lymph node metastasis: location of tumour within the lymph node*
- Subcapsular
- Intraparenchymal
- Both subcapsular and intraparenchymal

*Sentinel lymph node metastasis: extranodal extension*
- Not identified
- Present
- Indeterminate

*Sentinel lymph node metastasis: maximum single dimension of the largest discrete metastasis*

**G3.11**  Additional comment

**Synthesis and overview**

**S5.01**  *PATHOLOGICAL STAGING (AJCC 7TH Ed)*
Primary tumour (T) (Refer p 5)

**S5.02**  *PATHOLOGICAL STAGING (AJCC 7TH Ed)*
Regional lymph nodes (N)
- No nodes submitted or found
OR
(Refer p 5)
**G5.01 Diagnostic summary**

Specimen type, tumour site and laterality, tumour type, tumour pTpN stage, involvement of specimen margins

**S5.03 Year of publication and edition of staging system**

[Blank]

**S5.04 Overarching comment**

[Blank]

**PATHOLOGICAL STAGING (AJCC 7TH Ed)**

**T classification**

<table>
<thead>
<tr>
<th>T Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary Tumour cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of primary tumour</td>
</tr>
<tr>
<td>Tis</td>
<td>Melanoma in situ</td>
</tr>
<tr>
<td>T1</td>
<td>Melanomas ≤1.0 mm in thickness</td>
</tr>
<tr>
<td>T1a</td>
<td>Without ulceration and mitosis &lt;1/mm²</td>
</tr>
<tr>
<td>T1b</td>
<td>With ulceration or mitoses ≥ 1/mm²</td>
</tr>
<tr>
<td>T2</td>
<td>Melanomas 1.01–2.0 mm</td>
</tr>
<tr>
<td>T2a</td>
<td>Without ulceration</td>
</tr>
<tr>
<td>T2b</td>
<td>With ulceration</td>
</tr>
<tr>
<td>T3</td>
<td>Melanomas 2.01–4.0 mm</td>
</tr>
<tr>
<td>T3a</td>
<td>Without ulceration</td>
</tr>
<tr>
<td>T3b</td>
<td>With ulceration</td>
</tr>
<tr>
<td>T4</td>
<td>Melanomas &gt;4.0 mm</td>
</tr>
<tr>
<td>T4a</td>
<td>Without ulceration</td>
</tr>
<tr>
<td>T4b</td>
<td>With ulceration</td>
</tr>
</tbody>
</table>

**N classification**

<table>
<thead>
<tr>
<th>N Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>1 node</td>
</tr>
<tr>
<td>N1a</td>
<td>micrometastasis*</td>
</tr>
<tr>
<td>N1b</td>
<td>macrometastasis**</td>
</tr>
<tr>
<td>N2</td>
<td>2–3 nodes</td>
</tr>
<tr>
<td>N2a</td>
<td>micrometastasis*</td>
</tr>
<tr>
<td>N2b</td>
<td>macrometastasis**</td>
</tr>
<tr>
<td>N2c</td>
<td>in transit met(s)/satellite(s) without metastatic nodes</td>
</tr>
<tr>
<td>N3</td>
<td>4 or more metastatic nodes, or matted nodes, or in transit met(s)/satellite(s) with metastatic node(s)</td>
</tr>
</tbody>
</table>

* Micrometastases are diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).

** Macrometastases are defined as clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.